A systematic review of interventions for treatment resistant major depressive disorder in adolescents
- 529 Downloads
To update a comparative effectiveness review (1980–2011) of treatments for adolescents whose depressive episode or disorder (MDE/MDD) did not respond to one or more trials of SSRI antidepressants. MEDLINE, Cochrane Central, PsychINFO, Cochrane Database of Systematic Reviews, EMBASE, CINAHL, and AMED were searched in addition to the grey literature. We spanned May 2011 to September 1, 2017 and included only articles in English. 11 new studies were reviewed based on the criteria of having tested a comparative treatment in adolescents with MDD or MDE who were confirmed to have failed one or more SSRI trials. Data were extracted using standardized forms and a reference guide in DistillerSR; a second reviewer verified the accuracy of the data fields and discrepancies were resolved by consensus. One trial (N = 29) found a small benefit of escalating doses of fluoxetine and the treatment of adolescent depression study (TORDIA, N = 334) found significant benefits of combined SSRI or venlafaxine treatment with CBT for most outcomes. No new studies were identified since the previous review (2012). One trial is currently registered that will be a cross over trial of rTMS; other registered trials are open label. Multiple secondary data analyses of TORDIA have identified important predictors of treatment response and relapse. No new comparative studies were identified since the original review. Trials are desperately needed to identify new treatments for youth with SSRI resistant MDD. These youth should not be deemed as treatment resistant until completing one or two failed trials of SSRI combined with evidence-based psychotherapy.
KeywordsTreatment resistant depression Adolescent SSRI Systematic review
No specific funding was received to support the conduct of this systematic review.
Compliance with ethical standards
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
- 5.Depression in children and young people: Identification and management. National Institute for Health and Care Excellence Web site. Updated Sep 26, 2005. https://www.nice.org.uk/guidance/cg28/resources/depression-in-children-and-young-people-identification-and-management-pdf-975332810437. Accessed 13 Jan 2018
- 6.BeyondBlue (2011) Clinical practice guidelines: Depression in adolescents and young adults [Analysis brief on the Internet]. Melbourne: Beyondblue. https://resources.beyondblue.org.au/prism/file?token=BL/0890. Accessed 15 May 2018
- 11.Santaguida PL, MacQueen G, Keshavarz H, et al. (2012) Treatment for depression after unsatisfactory response to SSRIs [Analysis in brief on the Internet]. Rockville (MD): agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK97406/pdf/Bookshelf_NBK97406.pdf. Accessed 16 May 2018
- 13.Leggett LE, Soril LJ, Coward S, et al. (2015) Repetitive transcranial magnetic stimulation for treatment-resistant depression in adult and youth populations: a systematic literature review and meta-analysis. Prim Care Companion CNS Disord 17(6)Google Scholar
- 15.Heiligenstein JH, Hoog SL, Wagner KD et al (2006) Fluoxetine 40–60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10–20 mg: a pilot study. J Child Adolesc Psychopharmacol 16(1–2):207–217CrossRefPubMedGoogle Scholar
- 16.Evidence Partners, Ottawa, Canada [DistillerSR.]Google Scholar
- 18.Santaguida P, Raina P (2010) Hamilton: development of a quality assessment scale specific to harms in studies evaluating the efficacy of health technologies: manual for using the McHarm. https://effectivehealthcare.ahrg.gov/sites/defaul/files/methodsguide_chou_assessing_harms_when_cokmparing.pdf. Accessed 10 May 2019
- 19.Schünemann H, Brożek J, Guyatt G, et al. (2013) GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group. Available from guidelinedevelopment.org/handbook. Accessed 10 May 2019
- 25.Hilton RC, Rengasamy M, Mansoor B et al (2013) Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. J Am Acad Child Adolesc Psychiatry 52(5):482–492CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Lynch FL, Dickerson JF, Clarke G et al (2011) Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor–resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry 68(3):253–262CrossRefPubMedPubMedCentralGoogle Scholar
- 42.National Institute of Mental Health [NIMH] (1976) Clinical Global Improvement Scale and Clinical Global Assessment Scales. In: Edited by Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, ADM, pp 76–338.Google Scholar
- 50.McCauley E, Berk MS, Asarnow JR, Adrian M, Cohen J, Korslund K, Avina C, Hughes J, Harned M, Gallop R, Linehan MM (2018) Efficacy of dialectical behavior therapy for adolescents at high risk for suicide: a randomized clinical trial. JAMA Psychiatry 75(8):777–785CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Zhand N, Courtney DB, FLament MF (2015) Use of electroconvulsive therapy in adolescents with treatment-resistant depressive disorders a case series. J Electroconvuls Ther 31:238–245Google Scholar
- 53.Cullen KR, Amatya P, Roback MG, Albott CS, Westlund Schreiner M, Ren Y, Eberly LE, Carstedt P, Samikoglu A, Gunlicks-Stoessel M, Reigstad K, Horek N, Tye S, Lim KO, Klimes-Dougan B (2018) Intravenous ketamine for adolescents with treatment-resistant depression: an open-label study. J Child Adolesc Psychopharmacol 28(7):437–444. https://doi.org/10.1089/cap.2018.0030 (Epub 2018 Jul 13) CrossRefPubMedGoogle Scholar